Actualización práctica sobre la palmitoiletanolamida (PEAum) oral en el manejo del dolor crónico. Revisión narrativa

  1. Rafael Gálvez Mateos 1
  2. Antonio Aguilar Ros 2
  1. 1 Hospital Universitario Virgen de las Nieves (Granada)
  2. 2 Universidad CEU San Pablo
    info

    Universidad CEU San Pablo

    Madrid, España

    ROR https://ror.org/00tvate34

Revista:
MPJ Multidisciplinary Pain Journal

ISSN: 2697-2263

Año de publicación: 2023

Número: 1

Tipo: Artículo

DOI: 10.20986/MPJ.2023.1044/2023 DIALNET GOOGLE SCHOLAR lock_openAcceso abierto editor

Otras publicaciones en: MPJ Multidisciplinary Pain Journal

Objetivos de desarrollo sostenible

Resumen

ntroduction: Chronic pain is a cause of great suffering for patients and their relatives and one of the most relevant health issues. Available treatments, generally based on analgesic drugs, mainly NSAIDs, and othres, including opioids, achieve a partial and frequently temporary relief, with a large number of potential adverse effects. Development: New investigation lines of research in this field are looking to develop safe analgesics like ultramicronised palmitoylethanolamide (um-PEA), a nutritional oral supplementation administered at a dose of 600mg/12-24 hours, to counteract neuroinflammation, slow down pain chronicity, enhancing the antinociceptive effects of analgesic drugs. Conclusions: PEAum is a nutritional support showing analgesic, anti-inflammatory and nerve regenerative properties, indicated for use in case of chronic pain, specially neuropathic pain. Um-PEA is able to decrease pain preventing, partially, central sensitisation. Um-PEA safety profile and good tolerability represent an additional tool in the management of chronic pain.

Referencias bibliográficas

  • Mills SEE, Nicolson KP, Smith BH. Chronic pain: a review of its epidemiology and associated factors in population-based studies. Br J Anaesth. 2019;123(2):e273-e283. DOI: 10.1016/j.bja.2019.03.023.
  • Myers RR, Campana WM, Shubayev VI. The role of neuroinflammation in neuropathic pain: Mechanisms and therapeutic targets. Drug Discov Today. 2006;11(1-2):8-20. DOI: 10.1016/S1359-6446(05)03637-8. Ellis A, Bennett DLH. Neuroinflammation and the generation of neuropathic pain. Br J Anaesth. 2013;111(1):26-37. DOI: 10.1093/bja/aet128.
  • Ji RR, Xu ZZ, Gao YJ. Emerging targets in neuroinflammation-driven chronic pain. Nat Rev Drug Discov. 2014;13(7):533-48. DOI: 10.1038/nrd4334.
  • Brain K, Burrows TL, Rollo ME, Chai LK, Clarke ED, Hayes C, et al. A systematic review and meta-analysis of nutrition interventions for chronic noncancer pain. J Hum Nutr Diet. 2018;32(2):198-225. DOI: 10.1111/jhn.12601.
  • Chen Y, Xiang Q, Li C, Zeng Y, Dong J, Zhan P, et al. Nutritional Risk and Assessment for Patients with Cancer Pain. Nutr Cancer. 2022;74(1):168-74. DOI: 10.1080/01635581.2021.1882510.
  • Brain K, Burrows TL, Bruggink L, Malfliet A, Hayes C, Hodson FJ, et al. Diet and Chronic Non-Cancer Pain: The State of the Art and Future Directions. J Clin Med. 2021;10(21):5203. DOI: 10.3390/jcm10215203.
  • Tick H. Nutrition and Pain. Phys Med Rehabil Clin N Am. 2015;26(2):309-20. DOI: 10.1016/j.pmr.2014.12.006.
  • Guo R, Chen LH, Xing C, Liu T. Pain regulation by gut microbiota: molecular mechanisms and therapeutic potential. Brit J Anaesth. 2019;123(5):637-54. DOI: 10.1016/j.bja.2019.07.026.
  • Nijs J, Yilmaz ST, Elma Ö, Tatta J, Mullie P, Vanderweeën L, et al. Nutritional Intervention in Chronic Pain: Innovative Way of Targeting Central Nervous System Sensitization? Expert Opin Ther Targets. 2020;24(8):793-803. DOI: 10.1080/14728222.2020.1784142.
  • Levi-Montalcini R, Skaper SD, Toso RD, Petrelli L, Leon A. Nerve growth factor: From neurotrophin to neurokine. Trends Neurosci. 1996;19(11):514-20. DOI: 10.1016/S0166-2236(96)10058-8.
  • D’Amico R, Impellizzeri D, Cuzzocrea S, Di Paola R. ALIAmides Update: Palmitoylethanolamide and Its Formulations on Management of Peripheral Neuropathic Pain. Int J Mol Sci. 2020;21(15):5330. DOI: 10.3390/ijms21155330.
  • Ghafouri N, Ghafouri B, Larsson B, Stensson N, Fowler CJ, Gerdle B. Palmitoylethanolamideand and stearoylethanolamide levels in the interstitium of the trapezius muscle of women with chronic widespread pain and chronic neck-shoulder pain correlate with pain intensity and sensitivity. Pain. 2013;154(9):1649-58. DOI: 10.1016/j.pain.2013.05.002.
  • Petrosino S, Di Marzo V. The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations. Br J Pharmacol. 2017;174(11):1349-65. DOI: 10.1111/bph.13580.
  • Coburn A, Graham C, Haninger J. The effect of egg yolk in diets on anaphylactic arthritis (passive arthus phenomenon) in the guinea pig. J Exp Med. 1954;100(5):425-35. DOI: 10.1084/jem.100.5.425.
  • Kuehl F, Jacob T, Ganley O, Ormond R, Meisinger M. The identification of N-(2-hydroxyethyl)-palmitamide as a naturally occurring anti-inflammatory agent. J Am Chem Soc. 1957;79:5577-8. DOI: 10.1021/ja01577a066.
  • Gabrielsson L, Mattsson S, Fowler CJ. Palmitoylethanolamide for the treatment of pain: pharmacokinetics, safety and efficacy. Br J Clin Pharmacol. 2016;82(4):932-42. DOI: 10.1111/bcp.13020.
  • Palmidrol [Internet]. Drugbank; 2023 [Acceso en septiembre de 2022]. Disponible en: https://go.drugbank.com/drugs/DB14043.
  • Bot PLUS 2022 [Internet]. Consejo General de Colegios Oficiales de Farmacéuticos; 2023 [Acceso en septiembre de 2022]. Disponible en: https://botplusweb.portalfarma.com.
  • Clayton P, Hill M, Bogoda N, Subah S, Venkatesh R. Palmitoylethanolamide: A Natural Compound for Health Management. Int J Mol Sci. 2021;22(10):5305. DOI: 10.3390/ijms22105305.
  • Noli C, della Valle MF, Miolo A, Medori C, Shievano C; The Skinalia Clinical Research Group. Efficacy of ultra-micronized palmitoylethanolamide in canine atopic dermatitis: An open label multi-centre study. Vet Dermatol. 2015;26(6):432-40. DOI: 10.1111/vde.12250.
  • Petrosino S, Cordaro M, Verde R, Schiano Moriello A, Marcolongo G, Schievano C, et al. Oral ultramicronized palmitoylethanolamide: Plasma and tissue levels and spinal anti-hyperalgesic effect. Front Pharmacol. 2018;9:249. DOI: 10.3389/fphar.2018.00249.
  • Guida G, DeMartino M, De Fabiani A, Cantieri L A, Alexandre A, Vassallo G, et al. La palmitoilethanolamida (Normast) en el dolor neuropático crónico por lumbociatalgia de tipo compresivo: estudio clínico multicéntrico. Dolor. 2010;25:35-42.
  • Landolfo E, Cutuli D, Petrosini L, Caltagirone C. Effects of Palmitoylethanolamide on Neurodegenerative Diseases: A Review from Rodents to Humans. Biomolecules. 2022;12(5):667. DOI: 10.3390/biom12050667.
  • Ardizzone A, Fusco R, Casili G, Lanza M, Impellizzeri D, Esposito E, et al. Effect of Ultra-Micronized-Palmitoylethanolamide and Acetyl-l-Carnitine on Experimental Model of Inflammatory Pain. Int J Mol Sci. 2021;22(4):1967. DOI: 10.3390/ijms22041967.
  • Noce A, Albanese M, Marrone G, Di Lauro M, Pietroboni Zaitseva A, Palazzetti D, et al. Ultramicronized Palmitoylethanolamide (um-PEA): A New Possible Adjuvant Treatment in COVID-19 patients. Pharmaceuticals. 2021;14(4):336. DOI: 10.3390/ph14040336.
  • Briskey D, Mallard AR, Rao A. Increased Absorption of Palmitoylethanolamide Using a Novel Dispersion Technology System (LipiSperse). Nutraceuticals Food Sci. 2020;5(2)3.
  • Puglia C, Blasi P, Ostacolo C, Sommella E, Bucolo C, Platania CBM, et al. Innovative nanoparticles enhance N-palmitoylethanolamide intraocular delivery. Front Pharmacol. 2018;9:285. DOI: 10.3389/fphar.2018.00285.
  • Vacondio F, Bassi M, Silva C, Castelli R, Carmi, C Scalvini L, et al. Amino acid derivatives as palmitoylethanolamide prodrugs: Synthesis, in vitro metabolism and in vivo plasma profile in rats. PLoS ONE. 2015;10(6):e0128699. DOI: 10.1371/journal.pone.0128699.
  • Petrosino S, Schiano Moriello A, Cerrato S, Fusco M, Puigdemont A, De Petrocellis L, et al. The anti-inflammatory mediator palmitoylethanolamide enhances the levels of 2-arachidonoyl-glycerol and potentiates its actions at TRPV1 cation channels. Br J Pharmacol. 2016;173(7):1154-62. DOI: 10.1111/bph.13084.
  • Artamonov M, Zhukov O, Shuba I, Storozhuk L, Khmel T, Klimashevsky V, et al. Incorporation of labelled N-acylethanolamine (NAE) into rat brain regions in vivo and adaptive properties of saturated NAE under x-ray irradiation (1999). Ukr Biokhimicheskii Zhurnal. 2005;77(6):51-62.
  • Gula NM, Mel’nyk OO, Vysots’kyı MV, Balkov DI, Volkov GL, Govseieva NM. Distribution of [1-14C]N-palmitoylethanolamine and its metabolites in subcellular fractions of neuroblastoma C1300 N18 (1978). Ukr Biokhimicheskii Zhurnal. 1991;63: 115-9.
  • Kaczocha M, Glaser ST, Chae J, Brown DA, Deutsch DG. Lipid droplets are novel sites of N-acylethanolamine inactivation by fatty acid amide hydrolase-2. J. Biol Chem. 2010;285(4):2796-806. DOI: 10.1074/jbc.M109.058461.
  • Gabrielsson L, Gouveia-Figueira S, Häggström J, Alhouayek M, Fowler CJ. The anti-inflammatory compound palmitoylethanolamide inhibits prostaglandin and hydroxyeicosatetraenoic acid production by a macrophage cell line. Pharmacol Res Perspect. 2017;5(2):e00300. DOI: 10.1002/prp2.300.
  • Alhouayek M, Bottemanne P, Subramanian KV, Lambert DM, Makriyannis A, Cani PD, et al. N-Acylethanolamine-hydrolyzing acid amidase inhibition increases colon N-palmitoylethanolamine levels and counteracts murine colitis. FASEB J. 2015;29(2):650-61. DOI: 10.1096/fj.14-255208.
  • Rankin L, Fowler CJ. The Basal Pharmacology of Palmitoylethanolamide. Int J Mol Sci. 2020;21(21):7942. DOI: 10.3390/ijms21217942.
  • Scuteri D, Guida F, Boccella S, Palazzo E, Maione S, Rodríguez-Landa JF, et al. Effects of Palmitoylethanolamide (PEA) on Nociceptive Musculoskeletal and Neuropathic Pain: Systematic Review and Meta-Analysis of Clinical Evidence. Pharmaceutics. 2022;14(8):1672. DOI: 10.3390/pharmaceutics14081672.
  • Franceschi M, Scarcelli C, Niro V, Seripa D, Pazienza AM, Pepe G, et al. Prevalence, clinical features and avoidability of adverse drug reactions as cause of admission to a geriatric unit: A prospective study of 1756 patients. Drug Saf. 2008;31(6):545-56. DOI: 10.2165/00002018-200831060-00009.
  • Nørgaard A, Jensen-Dahm C, Gasse C, Hansen ES, Waldemar G. Psychotropic Polypharmacy in Patients with Dementia: Prevalence and Predictors. J Alzheimer’s Dis. 2017;56(2):707-16. DOI: 10.3233/JAD-160828.
  • Riedl L, Kiesel E, Hartmann J, Fischer J, Roßmeier C, Haller B, et al. A bitter pill to swallow—Polypharmacy and psychotropic treatment in people with advanced dementia. BMC Geriatr. 2022;22(1):214. DOI: 10.1186/s12877-022-02914-x.
  • Landi F, Onder G, Cesari M, Gambassi G, Steel K, Russo A, et al. Pain management in frail, community-living elderly patients. Arch Intern Med. 2001;161(22):2721-4. DOI: 10.1001/archinte.161.22.2721.
  • Rombolà L, Scuteri D, Marilisa S, Watanabe C, Morrone LA, Bagetta G, et al. Pharmacokinetic Interactions between Herbal Medicines and Drugs: Their Mechanisms and Clinical Relevance. Life. 2020;10(7):106. DOI: 10.3390/life10070106.
  • Nestmann ER. Safety of micronized palmitoylethanolamide (microPEA): Lack of toxicity and genotoxic potential. Food Sci Nutr. 2016;5(2):292-309. DOI: 10.1002/fsn3.392.
  • Paladini A, Fusco M, Cenacchi T, Schievano C, Piroli A, Varrassi G. Palmitoylethanolamide, a special food for medical purposes, in the treatment of chronic pain: a pooled data meta-analysis. Pain Physician. 2016;19(2):11-24.
  • De Filippis D, Negro L, Vaia M, Cinelli M, Iuvone T. New insights in mast cell modulation by palmitoylethanolamide. CNS Neurol Disord Drug Targets. 2013;12(1):78-83. DOI: 10.2174/1871527311312010013.
  • Verme JL, Fu J, Astarita G, La Rana G, Russo R, Calignano A, et al. The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol. 2005;67(1):15-19. DOI: 10.1124/mol.104.006353.
  • Ahluwalia J, Urban L, Bevan S, Nagy I. Anandamide regulates neuropeptide release from capsaicin-sensitive primary sensory neurons by activating both the cannabinoid 1 receptor and the vanilloid receptor 1 in vitro. Eur J Neurosci. 2003;17(12):2611-8. DOI: 10.1046/j.1460-9568.2003.02703.x.
  • Petrosino S, Palazzo E, De Novellis V, Bisogno T, Rossi F, Maione S, et al. Changes in spinal and supraspinal endocannabinoid levels in neuropathic rats. Neuropharmacology. 2007;52(2):415-22. DOI: 10.1016/j.neuropharm.2006.08.011.
  • Conti S, Costa, B, Colleoni, M, Parolaro D, Giagnoni, G. Antiinflammatory action of endocannabinoid palmitoylethanolamide and the synthetic cannabinoid nabilone in a model of acute inflammation in the rat. Br J Pharmacol. 2002;135(1):181-7. DOI: 10.1038/sj.bjp.0704466.
  • Costa B, Conti S, Giagnoni G, Colleoni M. Therapeutic effect of the endogenous fatty acid amide, palmitoylethanolamide, in rat acute inflammation: inhibition of nitric oxide and cyclooxygenase systems. Br J Pharmacol. 2002;137(4):413-20. DOI: 10.1038/sj.bjp.0704900.
  • Re G, Barbero R, Miolo A, Di Marzo V. Palmitoylethanolamide, endocannabinoids and related cannabimimetic compounds in protection against tissue inflammation and pain: Potential use in companion animals. Vet J. 2007;173(1):21-30. DOI: 10.1016/j.tvjl.2005.10.003.
  • Costa B, Comelli F, Bettoni I, Colleoni M, Giagnoni G. The endogenous fatty acid amide,palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: Involvement of CB(1), TRPV1 and PPARgamma receptors and neurotrophic factors. Pain. 2008;139(3):541-50. DOI: 10.1016/j.pain.2008.06.003.
  • Calignano A, La Rana G, Piomelli D, 2001. Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide. Eur J Pharmacol. 2001;419(2-3):191-8. DOI: 10.1016/S0014-2999(01)00988-8.
  • Farquhar-Smith WP, Rice ASC. 2003. A novel neuroimmune mechanism in cannabinoid-mediated attenuation of nerve growth factor-induced hyperalgesia. Anesthesiology. 2003;99(6):1391-401.
  • Helyes Z, Nemeth J, Than M, Bolcskei K, Pinter E, Szolcsanyi J. Inhibitory effect of anandamide on resiniferatoxin-induced sensory neuropeptide release in vivo and neuropathic hiperalgesia in the rat. Life Sci. 2003;73(18):2345-53. DOI: 10.1016/S0024-3205(03)00651-9.
  • Boccella S, Cristiano C, Romano R, Iannotta M, Belardo C, Farina A, et al. Ultra-micronized palmitoylethanolamide rescues the cognitive decline-associated loss of neural plasticity in the neuropathic mouse entorhinal cortex-dentate gyrus pathway. Neurobiol Dis. 2019;121:106-19. DOI: 10.1016/j.nbd.2018.09.023.
  • O’Brien, PD, Sakowski SA, Feldman EL. Mouse models of diabetic neuropathy. ILAR J. 2014;54(3):259-72. DOI: 10.1093/ilar/ilt052.
  • Pham VM, Matsumur S, Katano T, Funatsu N, Ito S. Diabetic neuropathy research: From mouse models to targets for treatment. Neural Regen Res. 2019;14(11):1870-9. DOI: 10.4103/1673-5374.259603.
  • Beijers AJM, Mols F, Vreugdenhil G. A systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration. Support Care Cancer. 2014;22(7):1999-2007. DOI: 10.1007/s00520-014-2242-z.
  • Donvito G,Wilkerson JL, Damaj MI, Lichtman AH. Palmitoylethanolamide Reverses Paclitaxel-Induced Allodynia in Mice. J Pharmacol Exp Ther. 2016;359(2):310-8. DOI: 10.1124/jpet.116.236182.
  • Birklein F, Ibrahim A, Schlereth T, Kingery WS. The rodent tibia fracture model: a critical review and comparison with the complex regional pain syndrome literature. J Pain. 2018;19(10):1102.e1-1102.e19. DOI: 10.1016/j.jpain.2018.03.018.
  • Farquhar-Smith WP, Jaggar SI, Rice AS. Attenuation of nerve growth factor-induced visceral hyperalgesia via cannabinoid CB(1) and CB(2)-like receptors. Pain. 2002;97(1-2):11-21. DOI: 10.1016/S0304-3959(01)00419-5.
  • Passavanti MB, Alfieri A, Pace MC, Pota V, Sansone P, Piccinno G, et al. Clinical applications of palmitoylethanolamide in pain management: protocol for a scoping review. Syst Rev. 2019;8(1):9. DOI: 10.1186/s13643-018-0934-z.
  • Schweiger V, Martini A, Bellamoli P, Donadello K, Schievano C, Balzo GD, et al. Ultramicronized Palmitoylethanolamide (um-PEA) as Add-on Treatment in Fibromyalgia Syndrome (FMS): Retrospective Observational Study on 407 Patients. CNS Neurol Disord Drug Targets. 2019;18(4):326-33. DOI: 10.2174/1871527318666190227205359.
  • Artukoglu BB, Beyer C, Zuloff-Shani A, Brener E, Bloch MH. Efficacy of Palmitoylethanolamide for Pain: A Meta-Analysis. Pain Physician. 2017;20(5):353-62.
  • Orefice NS, Alhouayek M, Carotenuto A, Montella S, Barbato F, Comelli A, et al. Oral Palmitoylethanolamide Treatment Is Associated with Reduced Cutaneous Adverse Effects of Interferon-β1a and Circulating Proinflammatory Cytokines in Relapsing–Remitting Multiple Sclerosis. Neurotherapeutics. 2016;13(2):428-38. DOI: 10.1007/s13311-016-0420-z.
  • Brotini S, Schievano C, Guidi L. Ultra-Micronized Palmitoylethanolamide: An Efficacious Adjuvant Therapy for Parkinson’s Disease. CNS Neurol Disord Drug Targets. 2017;16(6):705-13. DOI: 10.2174/1871527316666170321124949.
  • Schweiger V, Martini A, Bellamoli P, Donadello K, Schievano C, Del Balzo G, et al. Ultramicronized Palmitoylethanolamide (um-PEA) as Add-on Treatment in Fibromyalgia Syndrome (FMS): Retrospective Observational Study on 407 Patients. CNS Neurol Disord Drug Targets. 2019;18(4):326-33. DOI: 10.2174/1871527318666190227205359.
  • Ellis A, Bennett DLH. Neuroinflammation and the generation of neuropathic pain. Br J Anaesth. 2013;111(1):26-37. DOI: 10.1093/bja/aet128.
Fuente de los datos: Dialnet